CITATION REPORT List of articles citing

Lanthanum carbonate: safety data after 10 years

DOI: 10.1111/nep.12864 Nephrology, 2016, 21, 987-994.

Source: https://exaly.com/paper-pdf/64480813/citation-report.pdf

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
47	Lanthanum carbonate: safety data after 10 years. <i>Nephrology</i> , 2016 , 21, 987-994	2.2	41
46	Lanthanum deposition from oral lanthanum carbonate in the upper gastrointestinal tract. <i>Histopathology</i> , 2017 , 70, 1072-1078	7.3	27
45	All that glitters is not gold: A case of lanthanum carbonate aspiration. <i>SAGE Open Medical Case Reports</i> , 2017 , 5, 2050313X17712642	0.7	1
44	Bone-seeking agents for the treatment of bone disorders. <i>Drug Delivery and Translational Research</i> , 2017 , 7, 466-481	6.2	12
43	La(iii) biodistribution profiles from intravenous and oral dosing of two lanthanum complexes, La(dpp) and La(XT), and evaluation as treatments for bone resorption disorders. <i>Metallomics</i> , 2017 , 9, 902-909	4.5	7
42	Iron-based phosphate binders: a paradigm shift in the treatment of hyperphosphatemic anemic CKD patients?. <i>Journal of Nephrology</i> , 2017 , 30, 755-765	4.8	3
41	Lanthanum-Induced Mucosal Alterations in the Stomach (Lanthanum Gastropathy): a Comparative Study Using an Animal Model. <i>Biological Trace Element Research</i> , 2018 , 185, 36-47	4.5	10
40	Chitosan-Fe (III) Complex as a Phosphate Chelator in Uraemic Rats: A Novel Treatment Option. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018 , 122, 120-125	3.1	1
39	Long-Term Mortality and Bone Safety in Patients with End-Stage Renal Disease Receiving Lanthanum Carbonate. <i>Nephron</i> , 2018 , 140, 265-274	3.3	8
38	Lanthanum deposition corresponds to white lesions in the stomach. <i>Pathology Research and Practice</i> , 2018 , 214, 934-939	3.4	9
37	Evaluation of the effect of lanthanum carbonate hydrate on the pharmacokinetics of roxadustat in non-elderly healthy adult male subjects. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2018 , 43, 633-63	39 ^{2.2}	12
36	Sucroferric oxyhydroxide for the treatment of hyperphosphatemia. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 1137-1148	4	4
35	Lanthanum-containing bioparticles are associated with the influence of lanthanum on high phosphate mediated bone marrow stromal cells viability. <i>BioMetals</i> , 2018 , 31, 771-784	3.4	12
34	Ex vivo quantification of lanthanum and gadolinium in post-mortem human tibiae with estimated barium and iodine concentrations using K x-ray fluorescence. <i>Physiological Measurement</i> , 2019 , 40, 085	096	2
33	Frequent Involvement of the Duodenum with Lanthanum Deposition: A Retrospective Observational Study. <i>Internal Medicine</i> , 2019 , 58, 2283-2289	1.1	7
32	Lanthanides and tissue engineering strategies for bone regeneration. <i>Coordination Chemistry Reviews</i> , 2019 , 388, 248-267	23.2	18
31	Lanthanides compete with calcium for binding to cadherins and inhibit cadherin-mediated cell adhesion. <i>Metallomics</i> , 2019 , 11, 914-924	4.5	14

(2021-2019)

30	Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the IMpact of Phosphate Reduction On Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) study. <i>BMJ Open</i> , 2019 , 9, e024382	3	12
29	Lanthanum Deposition in the Gastroduodenal Mucosa of Dialysis Patients. <i>Journal of UOEH</i> , 2019 , 41, 387-395	1.6	1
28	Human health risk associated with the management of phosphorus in freshwaters using lanthanum and aluminium. <i>Chemosphere</i> , 2019 , 220, 286-299	8.4	41
27	Use of lanthanum for water treatment A matter of concern?. <i>Chemosphere</i> , 2020 , 239, 124780	8.4	22
26	Phosphate binders in chronic kidney disease: an updated narrative review of recent data. <i>Journal of Nephrology</i> , 2020 , 33, 497-508	4.8	21
25	Clinical Evaluation of the Safety, Efficacy and Tolerability of Lanthanum Carbonate in the Management of Hyperphosphatemia in Patients with End-Stage Renal Disease. <i>Therapeutics and Clinical Risk Management</i> , 2020 , 16, 871-880	2.9	1
24	Investigation of the clinical significance and pathological features of lanthanum deposition in the gastric mucosa. <i>BMC Gastroenterology</i> , 2020 , 20, 396	3	1
23	Lanthanum nanoparticles to target the brain: proof of biodistribution and biocompatibility with adjuvant therapies. <i>Nanomedicine</i> , 2020 , 15, 2107-2117	5.6	2
22	Investigating coherent normalization and dosimetry for the Am-La K XRF system. <i>Physiological Measurement</i> , 2020 , 41, 075014	2.9	1
21	Significant Species Differences in Intestinal Phosphate Absorption between Dogs, Rats, and Monkeys. <i>Journal of Nutritional Science and Vitaminology</i> , 2020 , 66, 60-67	1.1	6
20	Evaluation of toxicity profiles of rare earth elements salts (lanthanides). <i>Journal of Rare Earths</i> , 2021 , 39, 225-232	3.7	6
19	Evidence of an intestinal phosphate transporter alternative to type IIb sodium-dependent phosphate transporter In rats with chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2021 , 36, 68-75	4.3	8
18	The Decision to Initiate Dialysis in Children and Adolescents. 2021 , 115-129		1
17	Strong adsorption of phosphate by amorphous lanthanum carbonate nano-adsorbents. <i>Water Science and Technology</i> , 2021 , 83, 1605-1618	2.2	2
16	Lanthanum carbonate to control plasma and urinary oxalate level in type 1 primary hyperoxaluria?. <i>IJU Case Reports</i> , 2021 , 4, 235-238	0.5	О
15	The Importance of Phosphate Control in Chronic Kidney Disease. <i>Nutrients</i> , 2021 , 13,	6.7	5
14	Design and Rationale of HiLo: A Pragmatic, Randomized Trial of Phosphate Management for Patients Receiving Maintenance Hemodialysis. <i>American Journal of Kidney Diseases</i> , 2021 , 77, 920-930.6	e 1 ^{7·4}	7
13	In Search of an Efficient Complexing Agent for Oxalates and Phosphates: A Quantum Chemical Study. <i>Nanomaterials</i> , 2021 , 11,	5.4	О

12	Pharmacotherapy in chronic kidney disease hyperphosphatemia læffects on vascular calcification and bone health. <i>Makedonsko Farmacevtski Bilten</i> , 2017 , 63, 3-24	0.1	
11	Gastric lanthanosis (lanthanum deposition) in an immunosuppressed patient that discontinued lanthanum carbonate seven years ago. <i>Clinical Case Reports (discontinued)</i> , 2021 , 9, e05075	0.7	1
10	Lanthanum. 2022 , 419-425		
9	An update on phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a review of safety profiles <i>Expert Opinion on Drug Safety</i> , 2022 , 1-9	4.1	О
8	An open-label phase 2 trial to assess the efficacy, safety and pharmacokinetics of lanthanum carbonate in hyperphosphatemic children and adolescents with chronic kidney disease undergoing dialysis <i>BMC Nephrology</i> , 2022 , 23, 84	2.7	
7	EOS789, pan-phosphate transporter inhibitor, ameliorates the progression of kidney injury in anti-GBM-induced glomerulonephritis rats. <i>Pharmacology Research and Perspectives</i> , 2022 , 10,	3.1	O
6	Synthesis and characterization of a novel lanthanum (III) complex with a di(2-picolyl)amine-based ligand endowed with fluorescent properties. <i>Journal of Molecular Structure</i> , 2022 , 133398	3.4	O
5	Metabolomics of clinical samples reveal the treatment mechanism of lanthanum hydroxide on vascular calcification in chronic kidney disease. 2022 , 98, 361-377		
4	Earthworms Drive the Effect of La2O3 Nanoparticles on Radish Taproot Metabolite Profiles and Rhizosphere Microbial Communities.		О
3	Bone Disease in Children with Chronic Kidney Disease. 2022 , 356-378		O
2	Chitosan modified with lanthanum ions as implantable hydrogel for local delivery of bisphosphonates. 2023 , 230, 123429		О
1	Efficacy of Lanthanum Carbonate and Sevelamer Carbonate as Phosphate Binders in Chronic Kidney Disease Comparative Clinical Study. 2023 , 11, 27		O